VanEck Associates Portfolio holdings
AUM
$88.3B
This Quarter Return
+1.02%
1 Year Return
+29.35%
3 Year Return
+120.6%
5 Year Return
+164.76%
10 Year Return
+545.37%
AUM
$12.6B
AUM Growth
+$12.6B
(-3.1%)
Cap. Flow
-$319M
Cap. Flow
% of AUM
-2.53%
Top 10 Holdings %
Top 10 Hldgs %
25.36%
Holding
834
New
37
Increased
443
Reduced
280
Closed
71
Top Buys
| 1 |
CF Industries
CF
|
$76.7M |
| 2 |
B2Gold
BTG
|
$49.4M |
| 3 |
Patterson-UTI
PTEN
|
$36.8M |
| 4 |
VAR
Varian Medical Systems, Inc.
VAR
|
$35.9M |
| 5 |
IBM
IBM
|
$35.3M |
Top Sells
| 1 |
Cummins
CMI
|
$69.6M |
| 2 |
Franco-Nevada
FNV
|
$54.3M |
| 3 |
Agnico Eagle Mines
AEM
|
$52.9M |
| 4 |
Applied Materials
AMAT
|
$43.4M |
| 5 |
Procter & Gamble
PG
|
$39.7M |
Sector Composition
| 1 | Materials | 39.39% |
| 2 | Energy | 24.99% |
| 3 | Healthcare | 9.19% |
| 4 | Industrials | 3.9% |
| 5 | Technology | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Fortuna Silver Mines
FSM
$2.38B
| $21.4M | 0.17% |
9,518,906
+628,958
| +7% | +$1.42M |
|
127
IQVIA
IQV
$31.3B
| $21.1M | 0.17% |
306,774
+39,886
| +15% | +$2.74M |
|
|
RDC
128
DELISTED
Rowan Companies Plc
RDC
| $20.6M | 0.16% |
1,217,923
+118,048
| +11% | +$2M |
|
129
United Therapeutics
UTHR
$18.1B
| $20.4M | 0.16% |
130,496
+26,364
| +25% | +$4.13M |
|
|
DO
130
DELISTED
Diamond Offshore Drilling
DO
| $19.8M | 0.16% |
940,094
+103,998
| +12% | +$2.19M |
|
131
Pfizer
PFE
$141B
| $19.6M | 0.16% |
608,673
+53,572
| +10% | +$1.73M |
|
132
Coeur Mining
CDE
$8.93B
| $19.6M | 0.16% |
7,901,012
+155,499
| +2% | +$386K |
|
133
Harmony Gold Mining
HMY
$9.36B
| $19M | 0.15% |
20,458,479
-5,151,442
| -20% | -$4.79M |
|
134
Alkermes
ALKS
$4.94B
| $19M | 0.15% |
239,100
+31,352
| +15% | +$2.49M |
|
|
CNH
135
CNH Industrial
CNH
$14B
| $18.9M | 0.15% |
2,768,812
-386,374
| -12% | -$2.64M |
|
|
QGENF
136
DELISTED
QIAGEN NV
QGENF
| $18.6M | 0.15% |
673,047
+85,674
| +15% | +$2.37M |
|
137
Novo Nordisk
NVO
$252B
| $18.6M | 0.15% |
319,418
+20,862
| +7% | +$1.21M |
|
|
AGN
138
DELISTED
Allergan plc
AGN
| $18.5M | 0.15% |
59,150
+2,671
| +5% | +$835K |
|
139
GSK
GSK
$79.4B
| $18.5M | 0.15% |
457,925
+39,946
| +10% | +$1.61M |
|
140
Sanofi
SNY
$122B
| $18.4M | 0.15% |
430,546
+95,338
| +28% | +$4.07M |
|
141
Alnylam Pharmaceuticals
ALNY
$58.6B
| $18.3M | 0.14% |
193,870
+43,021
| +29% | +$4.05M |
|
142
Bristol-Myers Squibb
BMY
$96.6B
| $18.2M | 0.14% |
264,221
+5,890
| +2% | +$405K |
|
143
Credicorp
BAP
$20.7B
| $18.2M | 0.14% |
186,638
+46,450
| +33% | +$4.52M |
|
144
Merck
MRK
$210B
| $18.1M | 0.14% |
343,252
-705,335
| -67% | -$37.3M |
|
145
Ionis Pharmaceuticals
IONS
$9.6B
| $17.9M | 0.14% |
289,544
+24,350
| +9% | +$1.51M |
|
146
AbbVie
ABBV
$375B
| $17.3M | 0.14% |
291,565
+9,932
| +4% | +$588K |
|
|
SHPG
147
DELISTED
Shire pic
SHPG
| $16.9M | 0.13% |
82,650
+16,341
| +25% | +$3.35M |
|
148
Eli Lilly
LLY
$659B
| $16.9M | 0.13% |
200,342
+11,473
| +6% | +$967K |
|
149
AstraZeneca
AZN
$255B
| $16.6M | 0.13% |
487,522
+24,842
| +5% | +$843K |
|
150
Sunrun
RUN
$3.79B
| $16.5M | 0.13% |
1,403,900
-34,000
| -2% | -$400K |
|